DOCSLIB.ORG

Kdm6b Is Required for Self-Renewal of Normal and Leukemic Mouse Stem Cells Under Proliferative Stress Cates Mallaney Washington University in St

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kdm6b Is Required for Self-Renewal of Normal and Leukemic Mouse Stem Cells Under Proliferative Stress Cates Mallaney Washington University in St Washington University in St. Louis Washington University Open Scholarship Arts & Sciences Electronic Theses and Dissertations Arts & Sciences Summer 8-15-2018 Kdm6b is Required for Self-Renewal of Normal and Leukemic Mouse Stem Cells Under Proliferative Stress Cates Mallaney Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds Part of the Genetics Commons, and the Oncology Commons Recommended Citation Mallaney, Cates, "Kdm6b is Required for Self-Renewal of Normal and Leukemic Mouse Stem Cells Under Proliferative Stress" (2018). Arts & Sciences Electronic Theses and Dissertations. 1637. https://openscholarship.wustl.edu/art_sci_etds/1637 This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Human and Statistical Genetics Dissertation Examination Committee: Grant A. Challen, Chair Todd E. Druley Daniel C. Link Jeffrey A. Magee Laura G. Schuettpelz Matthew J. Walter Kdm6b is Required for Self-Renewal of Normal and Leukemic Mouse Stem Cells Under Proliferative Stress by Cates N. Mallaney A dissertation presented to The Graduate School of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy August 2018 St. Louis, Missouri © 2018, Cates N. Mallaney Table of Contents List of Figures .................................................................................................................. v List of Tables .................................................................................................................. vii Acknowledgments ......................................................................................................... viii Abstract .......................................................................................................................... xii Chapter 1: Introduction .................................................................................................... 1 1.1 Epigenetic Modifications are Dynamic and Reversible .......................................... 1 1.2 KDM6B as a Demethylase ..................................................................................... 2 1.3 KDM6B Plays an Important Role in Development .................................................. 5 1.4 KDM6B Regulates Transcription in a Demethylase-Independent Manner ............. 9 1.5 KDM6B as a Regulator of Inflammatory Response .............................................. 11 1.6 KDM6B as a Tumor Suppressor .......................................................................... 15 1.7 KDM6B as an Oncogene ..................................................................................... 17 1.8 KDM6B in Hematopoietic Malignancies ............................................................... 18 Chapter 2: Kdm6b is Required for Self-Renewal of Normal and Leukemic Stem Cells Under Proliferative Stress ............................................................................................. 20 2.1 Introduction .......................................................................................................... 20 2.2 Results ................................................................................................................. 21 2.2.1 Loss of Kdm6b results in depletion of phenotypic hematopoietic stem cells ..............21 2.2.2 Loss of Kdm6b results in depletion of functional long-term repopulating HSCs .........23 ii 2.2.3 Kdm6b is required for HSC self-renewal ...................................................................24 2.2.4 Kdm6b is required for self-renewal of leukemia-initiating cells ...................................25 2.2.5 Interferon response and NF-κB signaling are increased in Kdm6b-deficient HSCs ....26 2.2.6 Inflammatory stress forces differentiation of Kdm6b-deficient HSCs..........................28 2.2.7 Kdm6b is necessary for HSC maintenance in response to proliferative stress ..........31 2.3 Summary .............................................................................................................. 33 2.4 Methods ............................................................................................................... 36 2.4.1 Mice ..........................................................................................................................36 2.4.2 Bone Marrow Transplantation ...................................................................................36 2.4.3 Flow Cytometry .........................................................................................................37 2.4.4 Western Blotting ....................................................................................................... .39 2.4.5 H3K27me3 quantification ..........................................................................................39 2.4.6 LPS, pIpC, and 5-FU injections .................................................................................39 2.4.7 Methocult Plating.......................................................................................................40 2.4.8 Plasmids and Viral Transduction ...............................................................................40 2.4.9 Quantitative Real-Time PCR .....................................................................................41 2.4.10 RNA-SEQ data, quality control and analysis ...........................................................42 2.4.11 ChIPmentation ........................................................................................................43 2.4.12 Statistics..................................................................................................................44 2.5 Figures ................................................................................................................. 45 2.6 Tables .................................................................................................................. 74 iii Chapter 3: Discussion ................................................................................................... 96 3.1 Conclusions ......................................................................................................... 96 3.1.1 Introduction ...............................................................................................................96 3.1.2 Kdm6b in Stem Cell Fate Decisions ..........................................................................97 3.1.3 Regulation of Stress Response in Hematopoiesis Requires Kdm6b ..........................................................................................................................................98 3.1.4 Kdm6b as a Therapeutic Target for AML ................................................................. 100 3.2 Future Directions ................................................................................................ 101 3.2.1 Combinatorial Treatment of IFN and KDM6B inhibition ........................................... 101 3.2.2 Fos/Jun AP-1 Transcription Factor as a Possible Regulator of Kdm6b Demethylase- Independent Gene Expression ......................................................................................... 101 3.2.3 Does Genetic Inhibition of AP-1 Transcription Factor Genes Rescue Kdm6b Phenotype? ...................................................................................................................... 103 3.3 Figures ............................................................................................................... 105 3.4 Tables ................................................................................................................ 106 References .................................................................................................................. 107 iv List of Figures Figure 2.1: Loss of Kdm6b results in depletion of phenotypic hematopoietic stem cells45 Supplementary Figure 2.1.1: Loss of Kdm6b does not generate hematopoietic malignancies ................................................................................................................. 47 Supplementary Figure 2.1.2: Progenitor analysis in young and aged Kdm6b-deficient mice ............................................................................................................................... 49 Figure 2.2: Loss of Kdm6b results in depletion of functional long-term repopulating HSCs ............................................................................................................................. 51 Supplementary Figure 2.2.1: Progenitor analysis in young and aged Kdm6b-deficient mice ............................................................................................................................... 53 Supplementary Figure 2.2.2: WBM from aged mice shows depletion of functional repopulating HSCs ........................................................................................................ 54 Figure 2.3: Kdm6b is required for HSC self-renewal ..................................................... 56 Figure 2.4: Kdm6b is required for self-renewal of leukemia-initiating cells .................... 58 Supplementary Figure
Load more

Recommended publications
  • A Pathogenic Ctbp1 Missense Mutation Causes Altered Cofactor Binding and Transcriptional Activity
    neurogenetics (2019) 20:129–143 https://doi.org/10.1007/s10048-019-00578-1 ORIGINAL ARTICLE A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity David B. Beck1 & T. Subramanian2 & S. Vijayalingam2 & Uthayashankar R. Ezekiel3 & Sandra Donkervoort4 & Michele L. Yang5 & Holly A. Dubbs6 & Xilma R. Ortiz-Gonzalez7 & Shenela Lakhani8 & Devorah Segal9 & Margaret Au10 & John M. Graham Jr10 & Sumit Verma11 & Darrel Waggoner12 & Marwan Shinawi13 & Carsten G. Bönnemann4 & Wendy K. Chung14 & G. Chinnadurai2 Received: 23 October 2018 /Revised: 18 March 2019 /Accepted: 9 April 2019 /Published online: 30 April 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract We previously reported a pathogenic de novo p.R342W mutation in the transcriptional corepressor CTBP1 in four independent patients with neurodevelopmental disabilities [1]. Here, we report the clinical phenotypes of seven additional individuals with the same recurrent de novo CTBP1 mutation. Within this cohort, we identified consistent CtBP1-related phenotypes of intellectual disability, ataxia, hypotonia, and tooth enamel defects present in most patients. The R342W mutation in CtBP1 is located within a region implicated in a high affinity-binding cleft for CtBP-interacting proteins. Unbiased proteomic analysis demonstrated reduced interaction of several chromatin-modifying factors with the CtBP1 W342 mutant. Genome-wide transcriptome analysis in human glioblastoma cell lines expressing -CtBP1 R342 (wt) or W342 mutation revealed changes in the expression profiles of genes controlling multiple cellular processes. Patient-derived dermal fibroblasts were found to be more sensitive to apoptosis during acute glucose deprivation compared to controls. Glucose deprivation strongly activated the BH3-only pro-apoptotic gene NOXA, suggesting a link between enhanced cell death and NOXA expression in patient fibroblasts.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • Histone H3k27me3 Demethylases Regulate Human Th17 Cell Development and Effector Functions by Impacting on Metabolism
    Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism Adam P. Cribbsa,1, Stefan Terlecki-Zaniewicza, Martin Philpotta, Jeroen Baardmanb, David Ahernc, Morten Lindowd, Susanna Obadd, Henrik Oerumd, Brante Sampeye, Palwinder K. Manderf, Henry Penng, Paul Wordswortha, Paul Bownessa, Menno de Wintherh, Rab K. Prinjhaf, Marc Feldmanna,c,1, and Udo Oppermanna,i,j,k,1 aBotnar Research Center, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research Oxford Biomedical Research Unit, University of Oxford, OX3 7LD Oxford, United Kingdom; bExperimental Vascular Biology, Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, University of Amsterdam, 1105AZ Amsterdam, The Netherlands; cKennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, National Institute for Health Research Oxford Biomedical Research Unit, University of Oxford, OX3 7FY Oxford, United Kingdom; dRoche Innovation Center Copenhagen A/S, DK 2970 Hørsholm, Denmark; eMetabolon Inc., Durham, NC 27713; fEpinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D, SG1 2NY Stevenage, United Kingdom; gArthritis Centre, Northwick Park Hospital, HA13UJ Harrow, United Kingdom; hInstitute for Cardiovascular Prevention, Ludwig Maximilians University, 80336 Munich, Germany; iStructural Genomics Consortium, University of Oxford, OX3 7DQ Oxford,
    [Show full text]
  • A Mechanism of COOH–Terminal Binding Protein– Mediated Repression
    A Mechanism of COOH–Terminal Binding Protein– Mediated Repression Alison R. Meloni,1 Chun-Hsiang Lai,2 Tso-Pang Yao,2 and Joseph R. Nevins1,3 Departments of 1Molecular Genetics and Microbiology and 2Pharmacology and Cancer Biology and 3Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina Abstract repression involves the recruitment of histone deacetylase The E2F4 and E2F5 proteins specifically associate with (HDAC) to E2F site–containing promoters, presumably the Rb-related p130 protein in quiescent cells to repress resulting in an alteration of chromatin conformation that transcription of various genes encoding proteins hinders transcription (7-9). important for cell growth. A series of reports has Several observations suggest that additional events, inde- provided evidence that Rb-mediated repression involves pendent of HDAC recruitment, may contribute to the both histone deacetylase (HDAC)–dependent and repression. For example, many genes subject to E2F/Rb- HDAC-independent events. Our previous results mediated repression are not derepressed by treatment with the suggest that one such mechanism for Rb-mediated HDAC inhibitor trichostatin A (7). Moreover, Rb mutants that repression, independent of recruitment of HDAC, can no longer interact with HDAC are still capable of repressing involves the recruitment of the COOH-terminal binding transcription (10, 11). Based on these observations, it would protein (CtBP) corepressor, a protein now recognized to seem that HDAC-independent mechanisms of transcriptional play a widespread role in transcriptional repression. We repression contribute to the Rb control of transcription. Indeed, now find that CtBP can interact with the histone several Rb-interacting proteins, such as the chromatin remodel- acetyltransferase, cyclic AMP–responsive element– ing complex proteins BRG1 and human BRM, the methyl- binding protein (CREB) binding protein, and inhibit its transferase protein SUV39H1, and RBP1, have been shown to ability to acetylate histone.
    [Show full text]
  • Fine Tuning of Histone Demethylase KDM6A/B Improves the Development of Nuclear 4 Transfer Embryo 5
    bioRxiv preprint doi: https://doi.org/10.1101/390484; this version posted August 14, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title page 2 3 Fine Tuning of Histone Demethylase KDM6A/B Improves the Development of Nuclear 4 Transfer Embryo 5 6 Lei Yang1, 2, Lishuang Song1, 2, Xuefei Liu1, 2, Lige Bai1, 2, and Guangpeng Li1, 2, * 7 1 State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, 8 Inner Mongolia University, Hohhot 010070, China. 9 2 Research Center for Mammalian Reproductive Biology and Biotechnology, College of Life 10 Sciences, Inner Mongolia University, Hohhot 010070, China. 11 * Corresponding author. Tel: +86 471 4994329; E-mail: [email protected] 12 1 bioRxiv preprint doi: https://doi.org/10.1101/390484; this version posted August 14, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 13 Abstract 14 Despite the success of the production of animals by somatic cell nuclear transfer (SCNT) in 15 many species, the method is limited by a low efficiency. After zygotic genome activation 16 (ZGA), a large number of endogenous retroviruses (ERVs) are expressed, including the 17 murine endogenous retrovirus-L (MuERVL/MERVL). In this study, we generated a series of 18 MERVL-reporter mouse strains to detect the ZGA event in embryos. We found that the 19 majority of SCNT embryos exhibited ZGA failure, and histone H3 lysine 27 trimethylation 20 (H3K27me3) prevented SCNT reprogramming.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • The Leukemia-Associated Transcription Repressor AML1/MDS1/EVI1 Requires Ctbp to Induce Abnormal Growth and Di€Erentiation of Mu
    Oncogene (2002) 21, 3232 ± 3240 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and dierentiation of murine hematopoietic cells Vitalyi Senyuk1, Soumen Chakraborty1, Fady M Mikhail1,2, Rui Zhao1, Yiqing Chi1 and Giuseppina Nucifora*,1 1Department of Pathology and The Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA; 2Clinical Pathology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt The leukemia-associated fusion gene AML1/MDS1/ (ME) genes, is a product of the (3;21)(q26;q22) EVI1 (AME) encodes a chimeric transcription factor translocation that is associated with de novo and that results from the (3;21)(q26;q22) translocation. This therapy-related myelodysplastic syndrome/acute mye- translocation is observed in patients with therapy-related loid leukemia (t-MDS/AML) patients, and to a lesser myelodysplastic syndrome (MDS), with chronic myelo- extent with chronic myelogenous leukemia (CML) genous leukemia during the blast crisis (CML-BC), and patients during the blast crisis of their disease (Rubin with de novo or therapy-related acute myeloid leukemia et al., 1990; Nucifora et al., 1993). The AML1 gene (AML). AME is obtained by in-frame fusion of the (also known as CBFA2, PEBP2 or RUNX1) encodes AML1 and MDS1/EVI1 genes. We have previously the DNA-binding subunit of the core-binding tran- shown that AME is a transcriptional repressor that scription factor (CBF). AML1 interacts with the other induces leukemia in mice. In order to elucidate the role subunit of CBF, CBFb, which has no DNA-binding of AME in leukemic transformation, we investigated the domain.
    [Show full text]
  • KDM6B Rabbit Polyclonal Antibody – TA319844 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA319844 KDM6B Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: IF, WB Recommended Dilution: WB: 0.5 ug/mL, IF: 5 ug/mL Reactivity: Human, Mouse, Rat Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: JMJD3 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of human JMJD3. Formulation: JMJD3 Antibody is supplied in PBS containing 0.02% sodium azide. Concentration: 1ug/ul Purification: JMJD3 Antibody is affinity chromatography purified via peptide column. Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Gene Name: lysine demethylase 6B Database Link: NP_001073893 Entrez Gene 216850 MouseEntrez Gene 363630 RatEntrez Gene 23135 Human O15054 Background: JMJD3 Antibody: The Jumonji domain-containing protein 3 (JMJD3) functions as a trimethylation-specific demethylase, converting the trimethylated histone H3 Lys27 residue to the dimethylated form, and is thought to also function as a transcriptional repressor. JMJD3 plays a central role in regulation of posterior development, by regulating HOX gene expression. It is involved in inflammatory response by participating in macrophage differentiation in case of inflammation by regulating gene expression and macrophage differentiation. JMJD3 can also interact with and demethylate p53, resulting in its stabilization and localization to the nucleus in mouse embryo fibroblasts during neural stem cell differentiation. This product is to be used for laboratory only. Not for diagnostic or therapeutic use.
    [Show full text]
  • KDM6B/JMJD3 Histone Demethylase Is Induced by Vitamin D
    KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells Fabio Pereira1, Antonio Barbáchano1, Javier Silva2, Félix Bonilla2, Moray J. Campbell3, Alberto Muñoz1,*and María Jesús Larriba1,* 1Department of Cancer Biology, Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, E-28029 Madrid, Spain, 2Department of Medical Oncology, Hospital Universitario Puerta de Hierro, E- 28223 Majadahonda, Spain and 3Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA *To whom correspondence should be addressed. Instituto de Investigaciones Biomédicas “Alberto Sols”, Arturo Duperier 4, E-28029 Madrid, Spain. Tel: +34-915854451; Fax: +34- 915854401; Email: [email protected], [email protected] 1 Abstract KDM6B/JMJD3 is a histone H3 lysine demethylase with an important gene regulatory role in development and physiology. Here we show that human JMJD3 expression is induced by the active vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and that JMJD3 modulates the gene regulatory action of this hormone. 1,25(OH)2D3 activates the JMJD3 gene promoter and increases the level of JMJD3 RNA in human cancer cells. JMJD3 upregulation was strictly dependent on vitamin D receptor (VDR) expression and was abolished by cycloheximide. In SW480-ADH colon cancer cells, JMJD3 knockdown or expression of an inactive mutant JMJD3 fragment decreased the induction by 1,25(OH)2D3 of several target genes and of an epithelial adhesive phenotype. Moreover, JMJD3 knockdown upregulated the epithelial-to-mesenchymal transition inducers SNAIL1 and ZEB1 and the mesenchymal markers Fibronectin and LEF1, while it downregulated the epithelial proteins E-cadherin, Claudin-1 and Claudin-7.
    [Show full text]
  • Autism and Cancer Share Risk Genes, Pathways, and Drug Targets
    TIGS 1255 No. of Pages 8 Forum Table 1 summarizes the characteristics of unclear whether this is related to its signal- Autism and Cancer risk genes for ASD that are also risk genes ing function or a consequence of a second for cancers, extending the original finding independent PTEN activity, but this dual Share Risk Genes, that the PI3K-Akt-mTOR signaling axis function may provide the rationale for the (involving PTEN, FMR1, NF1, TSC1, and dominant role of PTEN in cancer and Pathways, and Drug TSC2) was associated with inherited risk autism. Other genes encoding common Targets for both cancer and ASD [6–9]. Recent tumor signaling pathways include MET8[1_TD$IF],[2_TD$IF] genome-wide exome-sequencing studies PTK7, and HRAS, while p53, AKT, mTOR, Jacqueline N. Crawley,1,2,* of de novo variants in ASD and cancer WNT, NOTCH, and MAPK are compo- Wolf-Dietrich Heyer,3,4 and have begun to uncover considerable addi- nents of signaling pathways regulating Janine M. LaSalle1,4,5 tional overlap. What is surprising about the the nuclear factors described above. genes in Table 1 is not necessarily the Autism is a neurodevelopmental number of risk genes found in both autism Autism is comorbid with several mono- and cancer, but the shared functions of genic neurodevelopmental disorders, disorder, diagnosed behaviorally genes in chromatin remodeling and including Fragile X (FMR1), Rett syndrome by social and communication genome maintenance, transcription fac- (MECP2), Phelan-McDermid (SHANK3), fi de cits, repetitive behaviors, tors, and signal transduction pathways 15q duplication syndrome (UBE3A), and restricted interests. Recent leading to nuclear changes [7,8].
    [Show full text]